January 10, 2024 11:01 AM ESTUpdated 11:22 AM
Deals
R&D

Co­herus ex­its TIG­IT deal with Jun­shi, three months af­ter Sur­face On­col­o­gy buy­out

Ayisha Sharma

News Reporter

Co­herus Bio­Sciences is walk­ing away from a three-year TIG­IT pact with Shang­hai Jun­shi Bio­sciences, sev­er­al months af­ter it ac­quired Sur­face On­col­o­gy and its TIG­IT drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times